Suggestions
Diana Verrilli
McKesson SVP, Corporate Strategy - Groundbreaking Healthcare Services & Solutions Executive l Oncology Subject Matter Expert l Steers Stakeholders Through Complex Change l Coveted Public Speaker/Board Governance Advisor
Diana Verrilli is an accomplished healthcare executive with extensive experience in strategy, business development, and practice management solutions. She currently serves as the Chief Growth Officer at DispatchHealth.1 Prior to this role, Verrilli had a long and successful career at McKesson Corporation spanning 23 years.12
During her tenure at McKesson, Verrilli held several senior leadership positions, including:
- Senior Vice President, Corporate Strategy & Business Development (2021-2023)2
- Senior Vice President, Strategy & Practice Solutions (2019-2021)2
- Senior Vice President, Payer and Practice Management Solutions (2016-2018)2
- Vice President & General Manager, Payer, Quality, and Provider Solutions (2015-2016)2
In these roles, Verrilli was responsible for developing and executing strategies for McKesson's payer, practice management, and revenue cycle solutions for a national network of 1,400 community oncologists.2 She oversaw value-based contracts, managed contracting, practice transformation, and clinical initiatives.2
Key achievements during her time at McKesson include:
- Overseeing 150 staff managing 650+ contracts with over $3B in payer revenue and $4B in GPO drug purchasing2
- Leading product portfolio strategy to drive growth in the oncology provider segment2
- Facilitating physician relationships and improving net promoter scores year over year2
- Guiding the negotiation of value-based care agreements with major insurance providers2
Verrilli holds a Bachelor of Arts in Economics from Smith College and a Master of Science in Health Policy and Management from the Harvard T.H. Chan School of Public Health.2
Recently, Diana Verrilli joined the Board of Directors of GelSana, a company developing innovative wound healing polymers.1 Her expertise in commercialization and business strategy is expected to be valuable as GelSana prepares to launch its first product, Cleragel™, in 2025.1

